0
Race through the weight loss drugs and obesity treatment is gaining new chapters. Mounjaro (Eli Lilly) and WeGovy and Ozepic (Novo Nordisk) manufacturers announced virtually together the positive results of developing a new crop of medicines, this time in tablets, which can
Novo Nordisk announced promising results for the Wegovy compressed version on Wednesday (17/9), just a day after competitor Eli Lilly
Read too
In the case of Novo, it is in reality, there is a medicine with this technology, the
Now the new has tested a 25 mg version of the active principle. In the study, 205 people took oral semaglute for 64 weeks. The group lost an average of 13% of the weight, against 2.2% in the placebo group. The most common adverse effects were nausea and indigestion.
The company reported that almost one in three participants reached weight loss of 20% or more. The pharmacist submitted the tablet to the United States Regulatory Agency, the FDA, and expects a decision by the end of the year. Pilot production has already begun in American factories.
What are the pens approved by Anvisa for
- O Mounjaro, which contains the tirzepatida as an active ingredient, it is manufactured by Eli Lilly. Studies have shown a reduction of up to 25% of body weight during use, one of the highest rates among approved therapies in the country for this purpose.
- O Wegovy and the Ozempic They have Semaglutado as an active ingredient. Both are manufactured by Novo Nordisk and have a weekly application indication.
- O Wegovy is indicated exclusively to treat obesity In patients with body mass index (BMI) above 30, or above 27 if there is any comorbidity. The application leads to an average loss of 20% of total mass in six months.
- O Ozepic should be used exclusively in control of type 2 diabetes. Nevertheless, many patients use it off-label to lose weight, which worries experts.
- O Victoza e o Saxenda They have liraglutide as an active ingredient-one of the first substances to activate LPG-1 receptors. These are the first injectable pens for the treatment of type 2 diabetes and should be used daily. Although they are not recommended for weight loss, studies show the loss of 6% of body weight in six months.
Dispute with the slimming pill
In the case of Eli Lilly, the announcement was also positive, but it is from a drug whose principle is not yet used. . In the new tablet that develops, however, she tests Orforgliprone.
The new principle showed positive results in study with 3,127 people. The highest dose led to an average loss of 12.4% of weight in 72 weeks. Almost 20% of participants reduced at least one fifth of body weight.
Adverse effects were similar to those observed with semaglutide. Most reported mild to moderate gastrointestinal discomfort. Still, analysts see a practical advantage in the tablet: it does not require fasting before use, which may attract patients.
The American company estimates that Orforgliprone could generate annual sales of up to $ 25 billion. It is expected that the request for approval will be sent to FDA later this year, which can accelerate product entry into the market.
New perspectives and likely more affordable price
GLP-1 drugs have gained popularity in recent years, but face criticism of cost, with higher doses costing more than two minimum wages in Brazil. The price, even, has been
Producing pills, however, is cheaper and easy to store, which can change this scenario, as well as expand range by ease of administration.
Follow the editorial of and stay on top of everything about it!
